Completed PHASE1 INTERVENTIONAL 2-arm NCT03468725

Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Doses of XEN1101

A Double-blind, Placebo-controlled Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Administration of XEN1101 in Healthy Male Subjects

Sponsor: Xenon Pharmaceuticals Inc.

Conditions Healthy Male Volunteers

Interventions Microcrystalline Cellulose XPF-008

Updated 6 times since 2018 Last updated: Sep 14, 2018 Started: Feb 13, 2018 Primary completion: Jul 31, 2018 Completion: Jul 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03468725, this PHASE1 trial focuses on Healthy Male Volunteers and remains completed. Sponsored by Xenon Pharmaceuticals Inc., it has been updated 6 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Oct 2018 — Jan 2021 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Jun 2018 — Oct 2018 [monthly]

Recruiting PHASE1

▶ Show 1 earlier version

Apr 2018 — Jun 2018 [monthly]

Recruiting PHASE1

First recorded

Feb 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Xenon Pharmaceuticals Inc.

Data source: Xenon Pharmaceuticals Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Brixton, United Kingdom